Francesca Barone
About Francesca Barone
Francesca Barone, M.D., Ph.D., is the Chief Scientific Officer known for her significant contributions to cancer immunotherapy and viral vector development.
Education and Expertise of Francesca Barone
Francesca Barone holds both an M.D. and a Ph.D., qualifying her with extensive knowledge and expertise in medical and scientific research. As the Chief Scientific Officer, her academic background and professional experience position her as an authority in the scientific community. Her dual degrees provide a strong foundation for her research and presentations in the field of immunotherapy and oncology.
Francesca Barone's Role as Chief Scientific Officer
Francesca Barone serves as the Chief Scientific Officer, a role that underscores her leadership in scientific research and development. Her position involves overseeing research initiatives, guiding scientific strategy, and leading teams in the pursuit of innovative therapeutic solutions. This role emphasizes her expertise and commitment to advancing the field of immunotherapy and cancer research.
Francesca Barone at the American Association for Cancer Research (AACR) Annual Meeting 2024
At the AACR Annual Meeting 2024, Francesca Barone presented on a first-in-class multimodal immunotherapy for the induction of tertiary lymphoid structures. This novel therapeutic strategy targets solid tumors, highlighting her pioneering approach in cancer treatment. Her presentation at this prestigious event showcases her contributions to advancing immunotherapy research.
Francesca Barone at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Francesca Barone made significant contributions to the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). She presented on the development of the enLIGHTEN Alpha-201 herpes simplex viral vectors targeting the tumor microenvironment. Additionally, she discussed a novel viral immunotherapeutic targeting the CD47/SIRPa axis, demonstrating potent anti-tumor effects. These presentations reflect her active involvement in cutting-edge cancer research and her role in pioneering new therapeutic strategies.
Francesca Barone at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Francesca Barone gave an oral presentation on safety and survival outcomes in recurrent high-grade glioma patients treated with CAN-3110, a first-in-class ICP34.5 expressing oncolytic HSV1, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). This presentation underscores her contributions to oncolytic viral therapy and her focus on improving treatment outcomes for high-grade glioma patients.
Francesca Barone at the 36th Annual Meeting of the Society for Neuro-Oncology (SNO)
At the 36th Annual Meeting of the Society for Neuro-Oncology (SNO), Francesca Barone presented on the detection of viral antigen and immune activation following intra-tumor injection of CAN-3110 in patients with recurrent high-grade glioma. This presentation highlights her research in the application of viral therapies to stimulate immune responses and target glioma tumors, contributing to the advancement of neuro-oncology research.